Comparing the efficacy and clinical outcome of telbivudine and entecavir naïve patients with hepatitis B virus-related compensated cirrhosis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 3, 2014, Pages 568-575

  Tsai, Ming Chao ^a,b   Yu, Hsien Chung ^c   Hung, Chao Hung ^a   Lee, Chuan Mo ^a,b   Chiu, King Wah ^a   Lin, Ming Tzung ^a,b   Tseng, Po Lin ^a,b   Chang, Kuo Chin ^a   Yen, Yi Hao ^a,b   Chen, Chien Hung ^a   Hu, Tsung Hui ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Chronic hepatitis B; Compensated cirrhosis; eGFR; Entecavir; Telbivudine

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; BILIRUBIN; CREATININE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; TELBIVUDINE; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; DRUG EFFICACY; END STAGE RENAL DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MODEL FOR END STAGE LIVER DISEASE SCORE; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEROCONVERSION; TREATMENT DURATION;

ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DISEASE PROGRESSION; DNA, VIRAL; FEMALE; GUANINE; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; THYMIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84897616150     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12436     Document Type: Article

References (36)

1. McMahon BJ. Epidemiology and natural history of hepatitis B. Semin. Liver Dis. 2005; 25 (Suppl. 1): 3-8.
2. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373: 582-592.
3. Chen YC, Chu CM, Yeh CT, Liaw YF. Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study. Hepatol. Int. 2007; 1: 267-273.
4. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
5. European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J. Hepatol. 2012; 57: 167-185.
6. Chang TT, Gish RG, de Man R etal. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 2006; 354: 1001-1010.
7. Lai CL, Shouval D, Lok AS etal. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2006; 354: 1011-1020.
8. Schiff E, Simsek H, Lee WM etal. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am. J. Gastroenterol. 2008; 103: 2776-2783.
9. Lai CL, Gane E, Liaw YF etal. Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med. 2007; 357: 2576-2588.
10. Liaw YF, Gane E, Leung N etal. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136: 486-495.
11. Chan HL, Chen YC, Gane EJ etal. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naive patients with HBV-related decompensated cirrhosis. J. Viral Hepat. 2012; 19: 732-743.
12. Brunetto MR. A new role for an old marker, HBsAg. J. Hepatol. 2010; 52: 475-477.
13. Brunetto MR, Moriconi F, Bonino F etal. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: 1141-1150.
14. Moucari R, Mackiewicz V, Lada O etal. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 1151-1157.
15. Wiegand J, Wedemeyer H, Finger A etal. A decline in hepatitis B virus surface antigen (hbsag) predicts clearance, but does not correlate with quantitative hbeag or HBV DNA levels. Antivir. Ther. 2008; 13: 547-554.
16. Borgniet O, Parvaz P, Bouix C etal. Clearance of serum HBsAg and anti-HBs seroconversion following antiviral therapy for chronic hepatitis B. J. Med. Virol. 2009; 81: 1336-1342.
17. Jung YK, Kim JH, Lee YS etal. Change in serum hepatitis B surface antigen level and its clinical significance in treatment-naive, hepatitis B e antigen-positive patients receiving entecavir. J. Clin. Gastroenterol. 2010; 44: 653-657.
18. Wursthorn K, Jung M, Riva A etal. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 2010; 52: 1611-1620.
19. Tsai MC, Lee CM, Chiu KW etal. A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice. J. Antimicrob. Chemother. 2012; 67: 696-699.
20. de Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992; 103: 1630-1635.
21. Locarnini S, Hatzakis A, Heathcote J etal. Management of antiviral resistance in patients with chronic hepatitis B. Antivir. Ther. 2004; 9: 679-693.
22. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
23. Wu MT, Lam KK, Lee WC etal. Albuminuria, proteinuria, and urinary albumin to protein ratio in chronic kidney disease. J. Clin. Lab. Anal. 2012; 26: 82-92.
24. Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J. Hepatol. 2012; 57: 442-450.
25. Keeffe EB, Zeuzem S, Koff RS etal. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin. Gastroenterol. Hepatol. 2007; 5: 890-897.
26. Gane EJ. The Roadmap concept: using early on-treatment virologic responses to optimize long-term outcomes for patients with chronic hepatitis B. Hepatol. Int. 2008; 2: 304-307.
27. Hosaka T, Suzuki F, Kobayashi M etal. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013; 58: 98-107.
28. Zoulim F, Durantel D, Deny P. Management and prevention of drug resistance in chronic hepatitis B. Liver Int. 2009; 29 (Suppl. 1): 108-115.
29. Lin SM, Yu ML, Lee CM etal. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J. Hepatol. 2007; 46: 45-52.
30. Nan XP, Zhang Y, Yu HT etal. Inhibition of viral replication downregulates CD4(+)CD25(high) regulatory T cells and programmed death-ligand 1 in chronic hepatitis B. Viral Immunol. 2012; 25: 21-28.
31. Chen Y, Li X, Ye B etal. Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B. Antiviral Res. 2011; 91: 23-31.
32. Chan HL, Wong VW, Chim AM, Chan HY, Wong GL, Sung JJ. Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. Aliment. Pharmacol. Ther. 2010; 32: 1323-1331.
33. Fede G, D'Amico G, Arvaniti V etal. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J. Hepatol. 2012; 56: 810-818.
34. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ etal. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2005; 352: 2673-2681.
35. Mauss S, Berger F, Schmutz G. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS 2005; 19: 93-95.
36. Gane EJ, Deray G, Piratvisuth T, Chan HL, Zeuzem S, Jia J. Renal function is improved for chronic hepatitis B (CHB) patients treated with telbivudine. Hepatology 2011; 54: 1044A.